Newbury Park, CA, United States of America

Ryan Paul Wurz

This inventor holds 30 USPTO granted patents and 16 published patent applications, plus 3 CIPO patents and 11 EPO patents, primarily in Cancer Therapeutics. Top assignees: Amgen Inc., Teijin Pharma Limited. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ryan Paul Wurz. Retrieved from https://idiyas.com/inventor/ryan-paul-wurz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 30 (Patent Applications = 16)

% Patents Active = 90.0

CIPO Patents = 3 (Patent Applications = 18)

EPO Patents = 11 (Patent Applications = 27)

Average Co-Inventor Count = 7.8

ph-index = 11

Forward Citations = 315(Granted Patents)

Location History:

Mewbury Park, CA (US) (2021)
Newbury Park, CA (US) (2010 - 2024)
Thousand Oaks, CA (US) (2019 - 2024)

Company Filing History:

Teijin Pharma Limited

patents

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

KRAS G12C Inhibitors

PIM Inhibitors

PI3 Kinase

mTOR

Macrocyclic Compounds

Substituted Piperazines

Azole Compounds

Pyrazolo Compounds

P38 Modulators

Amides

Bicyclic Compounds

Phthalazine Compounds

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715868 - SMARCA2-VHL degraders (2026-08-25),

2. 12583854 - KRAS G12C INHIBITORS AND METHODS OF USING THE SAME (2026-03-24),

3. 12570672 - Macrocyclic compounds and methods of use (2026-03-10),

4. 12440491 - KRAS G12C inhibitors and methods of using the same (2025-10-14),

5. 12083121 - Substituted piperazines as KRAS G12C inhibitors (2024-09-10),

6. 11993597 - Inhibitors of KRAS G12C and methods of using the same (2024-05-28),

7. 11905281 - KRAS G12C inhibitors and methods of using the same (2024-02-20),

8. 11766436 - KRAS G12C inhibitors and methods of using the same (2023-09-26),

9. 11306087 - Inhibitors of KRAS G12C and methods of using the same (2022-04-19),

10. 11285156 - Substituted piperazines as KRAS G12C inhibitors (2022-03-29),

11. 11096939 - KRAS G12C inhibitors and methods of using the same (2021-08-24),

12. 11090304 - KRAS G12C inhibitors and methods of using the same (2021-08-17),

13. 11053226 - KRAS G12C inhibitors and methods of using the same (2021-07-06),

14. 11045484 - KRAS G12C inhibitors and methods of using the same (2021-06-29),

15. 10988485 - KRAS G12C inhibitors and methods of using the same (2021-04-27),

Title: Innovations by Ryan Paul Wurz: A Trailblazer in Cancer Treatment

Introduction

Ryan Paul Wurz, based in Newbury Park, CA, is a prominent inventor recognized for his groundbreaking contributions to the field of cancer treatments. With an impressive portfolio of 26 patents, Wurz has made significant strides in developing innovative therapies aimed at combating serious disorders, particularly various types of cancer.

Latest Patents

Among his latest achievements are the patents related to Substituted Piperazines as KRAS G12C Inhibitors. These inventions detail compositions and methods for utilizing KRAS G12C inhibitors, which are invaluable for treating pancreatic, colorectal, and lung cancers. His work continues to push the boundaries of cancer research, offering hope for effective treatment options for patients afflicted by these diseases.

Career Highlights

Wurz's professional journey includes significant roles in leading biotechnology companies such as Amgen Inc. and Teijin Pharma Limited. His dedication to advancing medical science through innovative treatments has positioned him as a key player in the pharmaceutical industry.

Collaborations

Throughout his career, Ryan Paul Wurz has collaborated with esteemed colleagues, including Victor J Cee and Brian Alan Lanman. These partnerships have fostered a creative environment for innovation, enabling the development of cutting-edge solutions in cancer therapy.

Conclusion

Ryan Paul Wurz exemplifies the spirit of innovation and dedication in the realm of medical sciences. His contributions to cancer treatment through his patents signify not just personal achievement but also a considerable advancement in therapeutic options for millions. With his ongoing work, the future looks promising for cancer research and treatment methodologies.

Profile summary based on public USPTO records.